Impact of Morning Light Therapy in IBD
Not applicable · Testing Morning Light Therapy · 1 site · Icahn School of Medicine at Mount Sinai
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
This study is testing Morning Light Therapy (a device) as supportive care (to help with symptoms or quality of life). Condition(s) listed: Inflammatory Bowel Disease.
It is open-label: participants know what they are receiving.
This study does not use drug-development phases (it may test a device, diet, procedure, app, or care approach).
Who can join
- Ages 18 and older
- Any sex
Some of the main requirements, copied from the record:
- Patients with ulcerative colitis and signs of inflammation (Fecal calprotectin >150 mcg/g and/or CRP >5)
There are also 17 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 30 participants are expected to take part.
- The study has 1 group.
- Start date: 2026-07-01.
- Main results expected around 2027-07-01 (estimate from the record).
- 1 study site listed (1 marked recruiting) in United States.
Groups in this study
- Adult patients with Ulcerative Colitis (UC) (listed as: experimental group)
Main thing being measured
- C-reactive protein (CRP) level (week 4)
- Fecal Calprotectin (FCP) (week 4)
In the researchers’ words
The pilot study will focus on the effects of morning light therapy (MLT) in adult patients with ulcerative colitis (UC) who have evidence of poor sleep quality and active inflammation. The specific population is at risk for circadian rhythm sleep-wake disorders and has significant potential benefit from circadian realignment, which may lead to improved sleep quality and, ultimately, UC-related inflammatory activity.…
Words you might see
- Fecal calprotectin: a stool test that measures inflammation in the gut.
General definitions, not specific to this trial.
This summary was written automatically from the official record using fixed templates (no AI), so it only says what the record says, and may leave things out.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Not applicable |
| Study type | Interventional |
| Conditions | Inflammatory Bowel Disease |
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
| Enrollment | 30 (estimated) |
| Start date | 2026-07-01 |
| Primary completion (est.) | 2027-07-01 |
| First posted | 2025-10-03 |
| Last updated | 2026-10-09 |
| Official title | The Effects of Morning Light Therapy on IBD Activity and Symptoms |
| ClinicalTrials.gov ID | NCT07207200 |
Interventions
- Morning Light Therapy (Device)
One hour of morning light therapy each day for four weeks
Full eligibility criteria (from the record)
Inclusion Criteria: * Patients with ulcerative colitis and signs of inflammation (Fecal calprotectin >150 mcg/g and/or CRP >5) Exclusion Criteria: * Known pregnancy or currently lactating women * Current malignancy or active treatment for previously diagnosed malignancy. Patients with squamous and basal cell cancer of the skin are eligible for the study. * Serious co-morbidity including: Immunodeficiency, recent myocardial infarction or stroke, history of renal or hepatic failure, infection such as abscess, opportunistic infection, or sepsis. * Patients with pacemaker or defibrillators * The use of medications known to affect autonomic nervous system function, including but not limited to beta-blockers and benzodiazepines. * Comprehension of the English language not adequate to understand the questionnaires * Recent changes in IBD directed therapies within the last 3 months * Regular use of antidiarrheal agents. * Regular use of medications that have been shown to impair sleep (e.g. steroids, stimulants). If willing (and medically appropriate) to washout for 4 weeks, participant can be then enrolled in the study * Regular use of sleep medications including but not limited to: benzodiazepine hypnotics, non-benzodiazepine hypnotics, antipsychotics, and melatonin. If willing (and medically appropriate) to washout for 4 weeks, participant can be then enrolled in the study * Patients with prior colectomy or total proctocolectomy * History of any surgery within 3 months * Untreated Obstructive Sleep Apnea * Blindness or severely impaired, uncorrected vision * Employment which includes nocturnal shift work * Traveling multiple time zones within the study time frame * Any marijuana or illicit drugs use within one month of enrollment or ongoing basis
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Mount Sinai Hospital | New York, New York | United States | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.